US2005019915A1PendingUtilityA1
Antisense modulation of superoxide dismutase 1, soluble expression
Priority: Jun 21, 2001Filed: Sep 26, 2003Published: Jan 27, 2005
Est. expiryJun 21, 2021(expired)· nominal 20-yr term from priority
C12N 15/1137C12N 2310/346C12N 2310/341C12Y 115/01001C12N 2310/321C12N 2310/11C12N 2310/14C12N 2310/315A61K 38/00Y02P20/582C12N 2310/3341A61P 25/00
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
Claims
exact text as granted — not AI-modified1 . An antisense compound 8 to 50 nucleobases in length targeted to nucleobases 96-523 of a coding region of a nucleic acid molecule encoding human superoxide dismutase 1, soluble (SEQ ID NO: 3), wherein said compound specifically hybridizes with and inhibits the expression of human superoxide dismutase 1, soluble (SEQ ID NO: 3).
2 . The compound of claim 1 which is an antisense oligonucleotide.
3 . The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
4 . The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.
5 . The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
6 . The compound of claim 5 wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.
7 . The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
8 . The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.
9 . The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
10 . A method of inhibiting the expression of superoxide dismutase 1, soluble in brain and spinal cord, comprising intraventricularly administering to an animal a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding superoxide dismutase 1 so that expression of superoxide dismutase 1, soluble is inhibited.Join the waitlist — get patent alerts
Track US2005019915A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.